LENSAR (NASDAQ:LNSR) Given New $16.00 Price Target at Lake Street Capital

LENSAR (NASDAQ:LNSR) had its price objective boosted by equities researchers at Lake Street Capital from $12.00 to $16.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Lake Street Capital’s target price points to a potential upside of 31.80% from the stock’s current price.

LENSAR Stock Up 11.7 %

Shares of NASDAQ LNSR traded up $1.27 during trading on Friday, reaching $12.14. The company had a trading volume of 144,013 shares, compared to its average volume of 92,866. LENSAR has a 12-month low of $2.67 and a 12-month high of $13.03. The stock has a market cap of $141.01 million, a PE ratio of -8.32 and a beta of 0.66. The business’s 50-day moving average is $9.47 and its 200 day moving average is $6.99.

LENSAR (NASDAQ:LNSR) last posted its earnings results on Thursday, February 27th. The company reported ($1.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.40). LENSAR had a negative net margin of 34.03% and a negative return on equity of 49.02%. The firm had revenue of $16.73 million during the quarter, compared to the consensus estimate of $14.95 million.

Hedge Funds Weigh In On LENSAR

Several institutional investors have recently added to or reduced their stakes in LNSR. Evernest Financial Advisors LLC bought a new stake in shares of LENSAR during the 4th quarter worth approximately $174,000. Bailard Inc. bought a new position in shares of LENSAR in the 4th quarter worth $181,000. Atria Investments Inc raised its position in shares of LENSAR by 28.2% in the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company’s stock worth $233,000 after acquiring an additional 5,729 shares in the last quarter. Essex Investment Management Co. LLC raised its position in shares of LENSAR by 18.3% in the 4th quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company’s stock worth $357,000 after acquiring an additional 6,184 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in LENSAR by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock worth $460,000 after buying an additional 3,423 shares during the last quarter. Hedge funds and other institutional investors own 40.15% of the company’s stock.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.